Advanced therapies are innovative medicines for human use based on genes, cells or tissues, designed to treat the root cause of diseases rather than just their symptoms. Recognized by the European Medicines Agency (EMA) as advanced therapy medicinal products (ATMPs), they represent a new paradigm in biomedical innovation. These therapies act by repairing, replacing or reprogramming damaged cells or genetic material, offering long lasting and sometimes curative effects. They hold great promise for treating complex, chronic and rare diseases that currently have limited or no therapeutic options.
Catalonia is developing advanced therapies into accessible treatments for patients across Europe
What are ATMPs?
What are ATMPs?
How advanced therapies are transforming modern medicine
According to the European Medicines Agency (EMA), advanced therapies are classified into three main categories:
Additionally, some ATMPs may include one or more medical devices as an integral part of the product — in which case they are classified as combined advanced therapy medicinal products.
Discover our capabilities
Discover our capabilities
Catalonia’s leadership in advanced therapies
With scientific leadership, advanced clinical infrastructure and state-of-the-art GMP facilities, Catalonia is leading innovation in advanced therapies, bridging discovery and patient access with efficiency and quality.
By the numbers: Catalonia’s progress in advanced therapies
#3
In Europe for ATMP scientific publications and highly cited papers
#8
Worldwide and #5 in Europe in ATMP clinical trials
65
Active clinical trials in Catalonia (23 led by organizations from the BioRegion of Catalonia)
128
Preclinical assets under development in advanced therapies
7
Centers authorized by the Ministry to administer advanced therapy medicinal products (ATMPs)
7
Organizations with ATMP manufacturing capabilities in the Hub
804 m²
Of dedicated GMP manufacturing space and 34 cleanrooms supporting the production of advanced therapy medicinal products (ATMPs)
€470M
Secured by Catalan startups and scaleups in advanced therapies in recent years
Resources
This archive brings together key reports, white papers and expert publications on advanced therapies medicinal products (ATMPs) in Europe and globally, along with insights and strategic documents produced by ATMP Catalonia.
Scaling advanced therapies: Charting the next wave of growth and innovation
Deloitte
November 2025
Read more
Future trends in cell and gene therapies (2026-2030): Crisis, opportunity, or both?
Lluis Pareras – InVivo Partners
September 2025
Read more
Plan de Terapias Avanzadas en el Sistema Nacional de Salud 2025-2028
Ministerio de Sanidad (Government of Spain)
July 2025
Read more
Achieving CAR T-cell Therapy Health System Readiness: An Assessment of Barriers and Opportunities
IQVIA Institute for Human Data Science
March 2025
Read more
Retos y Oportunidades en la Era de las Terapias Avanzadas en España
Consorci de Salut i Social de Catalunya (CSC) & Pierre Fabre
March 2025
Read more
Healthcare in the post-COVID era, where is Cell and Gene Therapy going?
Sofinnova Partners
February 2025
Read more
Advanced Manufacturing Strategies to Increase the Reach of Cell and Gene Therapies: Takeaways from a Scientific Workshop
Alliance for Regenerative Medicine (ARM)
October 2024
Read more
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)
TERAV
March 2023
Read more
EMA pilot offers enhanced support to academic and non-profit developers of advanced therapy medicinal products
European Medicines Agency
Read more
Load more